Evidence map›Paper›PMID 40912472›Full record

Observational studyTransplantation and cellular therapy2025

The Clinical Utility of Real-Time Patient-Reported Outcomes in Cell Therapy Recipients.

Kenneth R Meehan, Julie R Doherty, Joel R King, Kate L Caldon, Christi Ann Hayes, John M Hill, Raphael A Lizcano, Megan M Holthoff, Elizabeth A O'Donnell, Paul Mills and 5 more

Abstract readObservational Study
In one paragraph

Observational study in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kenneth R MeehanTransplant and Cellular Therapy Program, Section of Hematology, Dartmouth-Hitchcock Medical Center, The Dartmouth Cancer Center, Lebanon, New Hampshire. Electronic address: kenneth.meehan@hitchcock.org.
Julie R DohertyThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Joel R KingThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Kate L CaldonTransplant and Cellular Therapy Program, Section of Hematology, Dartmouth-Hitchcock Medical Center, The Dartmouth Cancer Center, Lebanon, New Hampshire.
Christi Ann HayesTransplant and Cellular Therapy Program, Section of Hematology, Dartmouth-Hitchcock Medical Center, The Dartmouth Cancer Center, Lebanon, New Hampshire.
John M HillTransplant and Cellular Therapy Program, Section of Hematology, Dartmouth-Hitchcock Medical Center, The Dartmouth Cancer Center, Lebanon, New Hampshire.
Raphael A LizcanoTransplant and Cellular Therapy Program, Section of Hematology, Dartmouth-Hitchcock Medical Center, The Dartmouth Cancer Center, Lebanon, New Hampshire.
Megan M HolthoffThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Elizabeth A O'DonnellAlice Peck Day, Lebanon, New Hampshire.
Paul MillsDartmouth Health, Lebanon, New Hampshire.
Wenyan ZhaoThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Kimberley R HoltInformation Systems Division, Dartmouth Health, Lebanon, New Hampshire.
Eugene C NelsonThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Anna N A TostesonThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Aricca D Van CittersThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

The use of patient-reported outcome measures (PROMs) can improve a patient's clinical course by decreasing the incidence and severity of both physical and emotional treatment-related toxicities, uncover unmet patient needs, and assist in patients' shared decision-making. The objective of this study was to examine the feasibility and utility of using electronically captured "real time" agenda-setting questions and PROMs at the time of the patient's clinic visit. We designed a prospective observational study that employed a previsit questionnaire (PVQ) that included agenda-setting questions and the Patient-Reported Outcomes Measurement Information System 29-item profile survey, with results incorporated into a clinical decision support dashboard embedded within the patients' electronic medical record. The real-time results within the dashboard were used during each patient's clinic visit to encourage and support conversations between patients and their transplant clinician. Two hundred and thirty-seven consecutive cellular therapy recipients (allogeneic stem cell transplant, n = 98; autologous transplant, n = 106; or chimeric antigen receptor T cell, n = 33) seen between April 2022 and January 2025 were included. Over the study period, PVQ completion rates reached 80%, with an average of 60% weekly. The majority of patients (82%; n = 162) reported that the information in the dashboard helped them talk to their clinician about what mattered most, and 78% of patients (n = 154) noted that the dashboard helped them make healthcare decisions. Each of the transplant clinicians (n = 9) believed that the information gathered from the PVQ was helpful by aiding their discussions with the patient during the clinic visit. When using an internationally recognized and verified process to assess shared decision-making (CollaboRATE), 91% of patients (n = 180) believed that the dashboard assisted them in making future medical decisions. Eighty-nine percent of transplant clinicians agreed that the use of the PVQ aided patients in shared decision-making. Our results demonstrate the feasibility and utility of real-time PROMs and agenda-setting questions embedded within an electronic dashboard for cellular therapy patients. Both clinicians and patients noted marked benefits over the course of the study. These results support the ongoing need for capturing real-time PROMs with advantages to patients and their treating clinicians.

Indexed as

Cell- and Tissue-Based TherapyPatient Reported Outcome MeasuresAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesAgenda-settingElectronic health recordsHematopoietic stem cell transplantationPatient-centered carePatient-clinician relationship: surveys and questionnairesPatient-reported outcome measuresPrevisit planningShared decision-making

Identifiers

PMID40912472
PMCPMC13641013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.